SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AdventRX Pharmaceuticals, Inc. (Note: Request metadata referenced "Savara Inc," but the filing text identifies the registrant as AdventRX Pharmaceuticals, Inc.)
Filing Date: May 10, 2006
Reporting Period: Three months ended March 31, 2006
Event: Announcement of financial results for the quarter ended March 31, 2006.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that results were announced and directs readers to an attached press release (Exhibit 99.1) for detailed figures.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of results for the three months ended March 31, 2006.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the press release filed as Exhibit 99.1, which is incorporated by reference.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the press release dated May 10, 2006 (Exhibit 99.1).
- Confirm the company name discrepancy between the request metadata ("Savara Inc") and the filing registrant ("AdventRX Pharmaceuticals, Inc").
- Review the full text of the press release for any operational updates, clinical trial milestones, or liquidity concerns not summarized in this 8-K.